A phase I, open-label, dose escalation study evaluating high-dose gefitinib (IRESSA (R)) on weekly and twice weekly schedules in subjects with solid malignancies that are locally advanced, recurrent or metastatic.
Phase of Trial: Phase I
Latest Information Update: 12 May 2009
At a glance
- Drugs Gefitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 23 Jan 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov. Actual end date added.
- 14 Feb 2008 The expected completion date for this trial is now 1 Apr 2009.
- 11 Feb 2006 New trial record.